false
Catalog
Navigating Clinical Trials: Essential Knowledge fo ...
Practical Points in Psoriasis Studies
Practical Points in Psoriasis Studies
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. April Armstrong, a UCLA professor and chief of dermatology, shares insights on psoriasis clinical trials, which she's worked on for over 20 years. Her talk focuses on understanding inclusion and exclusion criteria, endpoints, and analysis methods in these studies, enabling better interpretation of trial results. Key inclusion criteria for systemic medications in moderate to severe plaque psoriasis often include a POSI score of 12 or more and BSA of at least 10%. Exclusion criteria usually rule out those with significant infections or psychiatric conditions. In terms of endpoints, systemic medications typically look at POSI-90 and clear or almost clear IgA. Dynamic endpoints assess changes over time, while static endpoints provide specific targets. Analysis methods like indirect comparisons help when no direct head-to-head trials are available, often using network meta-analysis to compare treatments indirectly. Understanding these aspects is crucial for evaluating and comparing clinical trial results effectively.
Asset Subtitle
by April Armstrong, MD, MPH, FAAD
Keywords
psoriasis clinical trials
inclusion criteria
exclusion criteria
endpoints
systemic medications
network meta-analysis
Legal notice
Copyright © 2025 American Academy of Dermatology. All rights reserved.
Reproduction or republication strictly prohibited without prior written permission.
×
Please select your language
1
English